Detailed price information for Iovance Biotherapeutics Inc (IOVA-Q) from The Globe and Mail including charting and trades.

Equity-Insider.com News Commentary -- The five-year cancer survival rate in the United States has reached a record 70%, reflecting decades of progress in early detection, targeted therapy, and ...

Iovance posts narrower Q4 loss as Amtagvi sales jump 33%. Shares soar on 50% ORR data and plans for registrational sarcoma study.

Investing.com -- Iovance Biotherapeutics Inc (NASDAQ:IOVA) shares jumped 32% Tuesday following positive early data from a pilot clinical trial of lifileucel in patients with advanced undifferentiated ...

The company announced encouraging early results from a pilot study evaluating its tumor-infiltrating lymphocyte therapy, ...

— Mec-V demonstrates median OS of 21.5 months in patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma compared with approximately 12 months with ...

Sarcomas of the head and neck are rare malignant tumors accounting for less than 1% of malignant tumors in this region and less than 10% of all soft tissue sarcomas. Head and neck sarcomas are mainly ...

Overall response rates with immune checkpoint inhibitors were high in patients with pleomorphic dermal sarcoma and cutaneous angiosarcoma. The efficacy of systemic therapy varies among patients with ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

The phase 3 INVINCIBLE-3 study of INT230-6 for soft tissue sarcomas continues without changes following Data Monitoring Committee safety review. The Data Monitoring Committee (DMC) for the ongoing ...